Korea Osimertinib Real world Evidence study to Assess safety and efficacy – PLUS - KOREA-PLUS

Inclusion Criteria

• 1. Eligible for, or on active study drug treatment according to the approved prescribing information;
• - The first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
• - Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who have been previously treated with EGFR TKI therapy
• - The adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
• 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative
• -